论文部分内容阅读
目的 探讨血管紧张素Ⅱ的Ⅰ型受体 (AT1)拮抗剂氯沙坦对高血压患者除降压作用外对血浆一氧化氮(N0 )的影响。方法 应用硝酸还原酶法对 10 0例高血压患者 (分为氯沙坦治疗组及洛汀新治疗组各 50例 )治疗前后及血压正常之对照组 3 0例的血浆N0浓度进行测定。结果 高血压组 (两组 )患者治疗前血浆N0浓度明显低于正常对照组 (P <0。 0 5) ,以氯沙坦和血管紧张素转换酶抑制剂 (A CEI)洛汀新有效降压后血浆N0浓度均有明显提高 ,差异有统计学意义 (P <0 0 5)。治疗前后两治疗组间的血浆N0浓度无差异。结论 氯沙坦与洛汀新除有良好的降压作用外均可升高高血压患者的血浆NO水平 ,并提示该两种药物降压治疗对患者血浆NO有相似的升高作用
Objective To investigate the effects of losartan, an angiotensin Ⅱ type 1 receptor (AT1) antagonist, on plasma nitric oxide (NO) in patients with essential hypertension except blood pressure. Methods Nitric acid reductase was used to determine plasma N0 level in 30 hypertensive patients (divided into losartan and loratin 50 cases) before and after treatment and normal blood pressure control group. Results The plasma N0 level in patients with hypertension before and after treatment was significantly lower than that in the normal control group (P0.05). Losartan and ACEI (Lotensin) were effectively reduced Post-pressure plasma N0 concentrations were significantly increased, the difference was statistically significant (P <0 05). There was no difference in plasma N0 concentration between the two treatment groups before and after treatment. Conclusions Both Losartan and Lotensin could elevate plasma NO levels in patients with hypertension except for their good antihypertensive effects and suggest that the antihypertensive treatment of these two drugs may have similar effects on NO in plasma